trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]amine | 142434-12-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]amine
• 英文别名: cis-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexane]amine；trans-2-(N-pyrrolidinyl)cyclohexyl-N-methylamine；cis-2-[1-pyrrolidinyl]-N-methylcyclohexylamine；trans-2-Pyrrolidinyl-N-methylcyclohexylamine；(+/-)-trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]amine；(1S,2S)-N-Methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-amine；N-methyl-2-(1-pyrrolidinyl)cyclohexanamine；N-methyl-2-pyrrolidin-1-ylcyclohexan-1-amine
• CAS: 142434-12-6
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.309
• InChiKey: MFOLKXSQEXMDIR-UHFFFAOYSA-N

物化性质

• 沸点：
  240.6±8.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]amine 以19%的产率得到
  参考文献：
  名称：

  CLARK, COLIN R.;HALFPENNY, PAUL R.;HILL, RAYMOND G.;HORWELL, DAVID C.;HUG+, J. MED. CHEM., 31,(1988) N 4, 831-836

  摘要：

  DOI：
• 作为产物：
  描述：

  氧化环己烯 以70%的产率得到trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]amine
  参考文献：
  名称：

  Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith

  摘要：

  通过向患者施用一种抗瘙痒化合物或其药用盐，以达到预防或治疗瘙痒的方法，所述化合物属于芳基乙酰胺类，该类化合物的示例包括具有以下结构的化合物：其中R1-4、X、X4、X5、X7、X9、Y和Z如规范中所述。

  公开号：

  US06239154B1

文献信息

• Kappa agonist compounds pharmaceutical formulations and method of
  申请人：Adolor Corporation

  公开号：US06057323A1

  公开（公告）日：2000-05-02

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided. The compound of formula I, having the structure: ##STR1## wherein R.sub.1, R.sub.2 ; X; and Ar Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物、含有这些化合物的组合物以及将它们用作镇痛剂和抗瘙痒剂的方法。具有结构的I式化合物：##STR1##其中R.sub.1，R.sub.2；X；和Ar Y，Z和n如规范中描述。
• Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
  申请人：Adolor Corporation

  公开号：US06239154B1

  公开（公告）日：2001-05-29

  Method for the prevention or treatment of pruritis by administering to a patient an antipruritic compound, or pharmaceutically acceptable salt thereof, of the class arylacetamide, which is exemplified by compounds of the formulae I, II, IIA, III, IV and IVA having the structures: and in which R1-4, X, X4, X5, X7, X9, Y and Z are as described in the specification.

  通过向患者施用一种抗瘙痒化合物或其药用盐，以达到预防或治疗瘙痒的方法，所述化合物属于芳基乙酰胺类，该类化合物的示例包括具有以下结构的化合物：其中R1-4、X、X4、X5、X7、X9、Y和Z如规范中所述。
• Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS
  申请人：G. D. Searle & Co.

  公开号：US05130330A1

  公开（公告）日：1992-07-14

  Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders and convulsions. Compounds of particular interest are of the formula ##STR1## wherein R.sup.1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms, and loweralkenylloweralkyl; wherein each of R.sup.2 and R.sup.3 is independently selected from hydrido and loweralkyl; wherein each of R.sup.4 through R.sup.7, R.sup.10 and R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

  描述了用于治疗中枢神经系统疾病如脑缺血、精神疾病和癫痫的某些含氮环杂环烷基氨基芳基化合物。特别感兴趣的化合物的结构如下：其中R.sup.1从氢、较低烷基、四至六个碳原子的环烷基烷基和较低烯基较低烷基中选择；其中R.sup.2和R.sup.3各自独立地选择自氢和较低烷基；其中R.sup.4到R.sup.7、R.sup.10和R.sup.11各自独立地选择自氢、羟基、较低烷基、苄基、苯氧基、苄氧基和卤代较低烷基；其中n是从四到六选择的数字；其中p是从零到四选择的数字；其中q是从三到五选择的数字；其中A从苯基、萘基和噻吩基中选择；其中上述任何A基可以进一步用一个或多个取代基独立选择自氢、羟基、较低烷基、较低烷氧基、卤、卤代较低烷基、氨基、单烷基氨基和双烷基氨基进行取代；或其药学上可接受的盐。
• Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
  申请人：Warner-Lambert Company

  公开号：US04663343A1

  公开（公告）日：1987-05-05

  Substituted naphthalenyloxy- or naphthalenylthiooxyamides of trans-1,2-diaminocyclohexanes possess selective kappa opioid receptor site binding activity and are thus useful as analgesic or diuretic agents. Methods of preparing the compounds, pharmaceutical compositions, and a method for their use as analgesic agents are also disclosed.

  取代萘氧基或萘硫氧基的trans-1,2-二氨基环己烷酰胺具有选择性kappa阿片受体结合活性，因此可用作镇痛或利尿剂。还公开了制备这些化合物的方法、制药组合物以及用作镇痛剂的方法。
• Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
  申请人：University of British Columbia

  公开号：US05506257A1

  公开（公告）日：1996-04-09

  The present invention provides methods for blocking sodium channels in cardiac or neuronal tissue using aminocyclohexylamides. This invention also provides kits including aminocyclohexylamides and instructions for the use of the compounds for the treatment of arrhythmia or for the inducement of local anaesthesia.

  本发明提供了使用氨基环己基酰胺阻断心脏或神经组织中钠通道的方法。本发明还提供了包括氨基环己基酰胺和使用该化合物治疗心律失常或诱导局部麻醉的说明书的试剂盒。